Copertina

Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiaofan Tian, Yichao Yu, Harshith Neeli, Dilara Jappar
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
di: Annie Lumen, et al.
Pubblicazione: (2024)

Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
di: Pamela Navarro‐Gonzales, et al.
Pubblicazione: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Pubblicazione: (2024)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
di: Yoo Jin Jang, et al.
Pubblicazione: (2024)

Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
di: Yow‐Ming C. Wang, et al.
Pubblicazione: (2024)

Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
di: Miramar Sami Kardouh, et al.
Pubblicazione: (2025)

Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites
di: Asma El‐Zailik, et al.
Pubblicazione: (2024)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
di: Cornelius Cilliers, et al.
Pubblicazione: (2024)

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
di: KyoungSoo Lim, et al.
Pubblicazione: (2024)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
di: Tetsuro Ogawa, et al.
Pubblicazione: (2025)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
di: Peiying Zuo, et al.
Pubblicazione: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
di: Yi‐An Bi, et al.
Pubblicazione: (2024)

American Society for Clinical Pharmacology and Therapeutics
Pubblicazione: (2026)

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
di: Sumit Bhatnagar, et al.
Pubblicazione: (2024)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes
di: Shih‐Hsuan Lin, et al.
Pubblicazione: (2026)

Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data
di: Yujing Li, et al.
Pubblicazione: (2024)

Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function
di: Elise Burmeister Getz, et al.
Pubblicazione: (2025)

Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
di: Prathap Nagaraja Shastri, et al.
Pubblicazione: (2024)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
di: John D. Davis, et al.
Pubblicazione: (2024)

Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
di: Anna L. Silverman, et al.
Pubblicazione: (2024)

HIV Pharmacology Data Repository: Setting the New Information‐Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies
di: Lauren A.R. Tompkins, et al.
Pubblicazione: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients
di: Eleanor A. Lisbon, et al.
Pubblicazione: (2025)

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
di: Million A. Tegenge, et al.
Pubblicazione: (2025)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
di: Emily Mannix, et al.
Pubblicazione: (2026)

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates
di: Andrew B. SyBing, et al.
Pubblicazione: (2025)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
di: Jatinder Kaur Mukker, et al.
Pubblicazione: (2025)

New Horizons for Clinical Pharmacology & Therapeutics : Global Outreach for Optimal Patient Outcomes
di: Karen Rowland Yeo
Pubblicazione: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
di: Peile Wang, et al.
Pubblicazione: (2024)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
di: Weihua Jiang, et al.
Pubblicazione: (2025)

Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
di: Polly Paul, et al.
Pubblicazione: (2025)

Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
di: Yan‐ou Yang, et al.
Pubblicazione: (2025)

Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®
di: Roberta Noseda, et al.
Pubblicazione: (2024)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment
di: Sébastien Taillemite, et al.
Pubblicazione: (2026)

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
di: Sara Belli, et al.
Pubblicazione: (2024)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
di: Ethan A. Poweleit, et al.
Pubblicazione: (2024)

Regulatory Perspective Based on Survey of Relationship Between Biopharmaceutical Characteristics and Food Effects on Systemic Pharmacokinetics
di: Naoko Honma, et al.
Pubblicazione: (2025)

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov
di: Lars Masanneck, et al.
Pubblicazione: (2024)

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
di: Chunhui Huang, et al.
Pubblicazione: (2024)

Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
di: Junghyun Cho, et al.
Pubblicazione: (2024)

A Reflection on the Evolution of Antibody‐Based Therapies in Oncology: Trastuzumab as an Exemplar—Commentary on Dijkers et al.
di: Sarah A. Holstein
Pubblicazione: (2025)